SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Status:
Not yet recruiting
Trial end date:
2026-10-23
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs
intravenous (IV) administration of isatuximab in combination with pomalidomide and
dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior
line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants
will be randomized 1:1 into 1 of 2 study arms:
Arm SC: Isatuximab SC + Pd
Arm IV: Isatuximab IV + Pd
Participants will be allowed to continue therapy until disease progression, unacceptable
adverse events (AEs), participant request to discontinue therapy or any other reason,
whichever comes first.